Lyka Labs Limited (LYKALABS.NS)
INR 110.34
(-0.31%)
INR 110.34
(-0.31%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 527.01 Million INR | -16.24% |
| 2022 | 629.19 Million INR | -50.96% |
| 2021 | 1.28 Billion INR | -20.99% |
| 2020 | 1.62 Billion INR | 14.17% |
| 2019 | 1.42 Billion INR | 48.46% |
| 2018 | 958.11 Million INR | -14.17% |
| 2017 | 1.11 Billion INR | -6.3% |
| 2016 | 1.19 Billion INR | 11.95% |
| 2015 | 1.06 Billion INR | 29.37% |
| 2014 | 822.59 Million INR | -27.52% |
| 2013 | 1.13 Billion INR | -6.36% |
| 2012 | 1.21 Billion INR | -1.98% |
| 2011 | 1.23 Billion INR | 13.12% |
| 2010 | 1.09 Billion INR | 7.3% |
| 2009 | 1.01 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 498.9 Million INR | 317.89% |
| 2023 Q1 | 119.38 Million INR | -81.03% |
| 2023 FY | 527.01 Million INR | -16.24% |
| 2023 Q4 | 527.01 Million INR | 1160.62% |
| 2023 Q3 | 41.8 Million INR | -91.62% |
| 2022 Q3 | 166.04 Million INR | -85.32% |
| 2022 Q2 | 1.13 Billion INR | 527.82% |
| 2022 Q1 | 180.19 Million INR | -85.96% |
| 2022 FY | 629.19 Million INR | -50.96% |
| 2022 Q4 | 629.19 Million INR | 278.93% |
| 2021 FY | 1.28 Billion INR | -20.99% |
| 2021 Q2 | 1.13 Billion INR | 1386.5% |
| 2021 Q3 | 112.06 Million INR | -90.12% |
| 2021 Q1 | 76.3 Million INR | -95.3% |
| 2021 Q4 | 1.28 Billion INR | 1045.01% |
| 2020 Q4 | 1.62 Billion INR | 2087.09% |
| 2020 Q3 | 74.25 Million INR | -94.72% |
| 2020 Q2 | 1.4 Billion INR | 1080.66% |
| 2020 Q1 | 119.19 Million INR | -91.62% |
| 2020 FY | 1.62 Billion INR | 14.17% |
| 2019 Q4 | 1.42 Billion INR | 1809.33% |
| 2019 FY | 1.42 Billion INR | 48.46% |
| 2019 Q3 | 74.49 Million INR | -91.91% |
| 2019 Q2 | 920.5 Million INR | 1704.21% |
| 2019 Q1 | 51.02 Million INR | -94.67% |
| 2018 Q1 | 62.27 Million INR | 0.0% |
| 2018 FY | 958.11 Million INR | -14.17% |
| 2018 Q4 | 958.11 Million INR | 0.0% |
| 2017 FY | 1.11 Billion INR | -6.3% |
| 2016 Q4 | 801.17 Million INR | 1421.38% |
| 2016 Q1 | 55.55 Million INR | -95.23% |
| 2016 Q2 | 849.52 Million INR | 1429.25% |
| 2016 FY | 1.19 Billion INR | 11.95% |
| 2016 Q3 | 52.66 Million INR | -93.8% |
| 2015 FY | 1.06 Billion INR | 29.37% |
| 2015 Q2 | 675.88 Million INR | 936.98% |
| 2015 Q4 | 1.16 Billion INR | 72.42% |
| 2015 Q1 | 65.17 Million INR | -95.06% |
| 2015 Q3 | 675.88 Million INR | 0.0% |
| 2014 Q4 | 1.31 Billion INR | 0.0% |
| 2014 Q1 | 1.06 Billion INR | 0.0% |
| 2014 FY | 822.59 Million INR | -27.52% |
| 2013 Q3 | 28.17 Million INR | -97.74% |
| 2013 Q1 | 1.44 Billion INR | 19.28% |
| 2013 FY | 1.13 Billion INR | -6.36% |
| 2013 Q2 | 1.24 Billion INR | -13.85% |
| 2012 Q4 | 1.21 Billion INR | 0.0% |
| 2012 FY | 1.21 Billion INR | -1.98% |
| 2012 Q3 | - INR | 100.0% |
| 2012 Q2 | -65.04 Million INR | 0.0% |
| 2011 FY | 1.23 Billion INR | 13.12% |
| 2010 FY | 1.09 Billion INR | 7.3% |
| 2009 FY | 1.01 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Biocon Limited | 140.18 Billion INR | 99.624% |
| Blue Jet Healthcare Limited | -830.93 Million INR | 163.424% |
| Concord Biotech Limited | -54.04 Million INR | 1075.137% |
| Dishman Carbogen Amcis Limited | 18.99 Billion INR | 97.225% |
| Jubilant Ingrevia Limited | 6.6 Billion INR | 92.023% |
| Panacea Biotec Limited | -1.18 Billion INR | 144.477% |
| Piramal Pharma Limited | 42.27 Billion INR | 98.753% |
| SMS Lifesciences India Limited | 992.31 Million INR | 46.89% |
| Supriya Lifescience Limited | -694.68 Million INR | 175.864% |
| Syngene International Limited | -83 Million INR | 734.955% |
| TAKE Solutions Limited | 361.37 Million INR | -45.838% |
| Zota Health Care Limited | 942.79 Million INR | 44.101% |